For a New Implant, a Medicare Payment Code Is the Market Gate

The part of a medical device that gets written up is almost never the part that decides whether it makes money. A neuromodulation implant that runs without a battery inside the patient is a real engineering achievement, and it will get the press. Whether it has a market got settled somewhere much quieter, inside a Medicare payment table. This month Neuspera Medical pointed straight at that table, and the move is a cleaner lesson in commercialization than most funding announcements.

What CMS actually did

Neuspera makes an integrated sacral neuromodulation system, an implant used to treat urinary urge incontinence. The word integrated is doing work here: the system is powered from outside the body, so there is no implanted battery to replace in a second surgery later. On July 8 the company said the Centers for Medicare and Medicaid Services had assigned its billing code to payment level APC 5464 in the proposed 2027 Outpatient Prospective Payment System rule. In practice, its externally powered device would sit at the same Medicare payment as every other implantable neuromodulation therapy for that condition. The proposed rule also raises the payment for that group to $22,150 for 2027, an 11.8 percent increase over 2026. A year earlier the device had already been added to Medicare’s national coverage determination for sacral nerve stimulation. Coverage plus payment parity is the combination that opens the door. The market it is walking into runs about a billion dollars a year and has belonged to Boston Scientific and Medtronic.

Why parity beats a premium

A founder’s instinct is to want a bigger number. A novel device, the reasoning goes, deserves a new-technology code and a premium rate that reflects how different it is. That instinct is usually wrong. A brand-new code is one a hospital’s billing staff has never run, a payment level that can be revised later, and a reason for a value-analysis committee to wait and watch. Parity with the incumbents does the opposite. It drops the new device into a payment slot the buyer already trusts, already bills against, and already budgets for. The engineering can be genuinely new while the reimbursement stays boringly familiar, and boring is what gets a purchase order signed. What Neuspera actually bought is that a hospital no longer has to take a payment risk to try something unproven.

The gate founders skip

Founders map the FDA pathway obsessively and file reimbursement under later, something to sort out after clearance and the first few sales. That order is backwards. A clearance lets you legally sell a device. A payment code decides whether anyone can afford to buy it. Those are two separate gates, run by two separate agencies, on two separate clocks, and the second one sets the size of your market. Payment rules also move on their own annual cycle, which means the reimbursement answer can shift the year after you launch. I tell founders to bring the CFO and a coding expert into the room before the surgeons fall in love with the device, because they, not the surgeon, model whether the hospital gets paid. This is not only a medtech tax. A diagnostics startup waiting on a CPT code, or an energy-hardware company whose payback depends on a utility tariff, is standing at the same gate. Map the payment path before you lock the bill of materials. If the economics do not close for the buyer, a clean clearance is still a device nobody can order.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →